Acticor Biotech
Manufacturing · France · 11-50 Employees
View Company Info for Free
Overview
Headquarters
27 Rue Du Faubourg Saint Jacques, Paris,...Phone Number
+33 676233813Website
www.acticor-biotech.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Acticor Biotech
Acticor Biotech is a clinical stage biopharmaceutical company focused on developing innovative treatments for thrombotic diseases, particularly acute ischemic stroke. Their primary product, Glenzocimab, is a first-in-class drug designed for use in cardiovascular emergencies and acute thrombotic conditions. The company is a spin-off from the French National Institute of Health and Medical Research (INSERM) and aims to address significant medical needs in the treatment of stroke. Acticor Biotech targets healthcare providers and institutions involved in the management of cardiovascular diseases.Explore more
Acticor Biotech Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Acticor Biotech your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Acticor Biotech had a recent Job posting/layoffs
Product Launch: Get notified when Acticor Biotech launches new products
Funding: Get notified immidiatlly once Acticor Biotech has new funding data
Acticor Biotech, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Acticor Biotech is spiking on competitors!
Check if Acticor Biotech has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Acticor Biotech recently announced quarterly report
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Acticor Biotech
Recommended Actions
Find VP level buyers at Acticor Biotech
Find 2 more new buyers
Company Profile Activity
Activity Insights
Acticor Biotech is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Acticor Biotech is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Acticor Biotech.
Acticor Biotech financials insights
Gather financial insights about Acticor Biotech, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Private Equity
$1.5M
2017
Private Equity
$1.6M
2018
Series A
$2M
2019
Series B
$7.6M
Acticor Biotech Tech Stack
A closer look at the technologies used by Acticor Biotech
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
Executive Moves, New Hire
Left Company
Executive Move
Executive Moves, Left Company
Event
Events
New Hire
Executive Move
Board of Directors
Acticor Biotech News & Media
ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares ... - Business Wire
Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovativACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares ... - Business Wire
Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovativActicor adapts its ACTISAVE clinical study to prepare the - GlobeNewswire
ACTICOR adapts its ACTISAVE clinical study to prepare the registration of glenzocimab for the treatment of stroke Clinical results from ACTISAVE phase...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Acticor Biotech
Sign Up For FreeTo access detailed company insights
Acticor Biotech is a clinical stage biopharmaceutical company focused on developing innovative treatments for thrombotic diseases, particularly acute ischemic stroke. Their primary product, Glenzocimab, is a first-in-class drug designed for use in cardiovascular emergencies and acute thrombotic conditions. The company is a spin-off from the French... Read More
